Department of Hematology

Hematology Home >

  • Faculty
Hematology
  •  
  •  
  •  
  •  
  •  
  •  
  •  
faculty photo

David L. Porter, MD

Professor of Medicine at the Hospital of the University of Pennsylvania
Director, Blood and Marrow Transplantation
Department: Medicine
Contact information
Hematology-Oncology
3400 Civic Center Boulevard
PCAM 2 West Pavillion
Philadelphia, PA 19104
Office: 2156622862
Fax: 2156155888
Email: david.porter@uphs.upenn.edu
Education:
B.A. (Biochemistry)
University of Rochester, 1981.
 M.D. (Medicine)
Brown University, 1987.
Post-Graduate Training
Medical Intern, University Hospital, BU Med. Ctr., Boston, 1987-1988.
 Junior Assistant Resident, University Hospital, Boston, 1988-1989.
 Senior Assistant Resident, University Hospital, Boston, 1989-1990.
 Clinical Fellow in Hematology-Oncology, Brigham and Women's Hosp., Boston, 1990-1991.
 Clinical Fellow in Hematology-Oncology, Harvard Medical School, Boston, 1990-1991.
 Research Fellow in Hematology-Oncology, Harvard Medical School, Boston, 1991-1993.
 Research/Clinical Fellow in Hematology-Oncology, Brigham & Women's Hospital, Boston, 1991-1993.
Certifications
American Board of Internal Medicine, Certificate No. 130268, 1990.
 Subspecialty in Medical Oncology American Board of Internal Medicine , 1993.
 Subspecialty in Hematology American Board of Internal Medicine , 1994.
 Subspecialty in Hematology American Board of Internal Medicine , 2006.
Permanent link
 
> School of Medicine   > Faculty   > Details

Selected Publications

Hagen EA, Stern H, Porter D, Duffy K, Foley K, Luger S, Schuster S , Stadtmauer E, Schuster MG.: High Rate of Invasive Fungal Infections Following Nonmyeloablative Allogeneic Transplantation, Clinical Infectious Disease. 36: 9-15, 2003.

 Loren AW, Luger SM, Duffy KM, Stadtmauer E, Tsai D, Schuster S, Nasta S, Klumpp T, Orloff G, Porter D. : Alemtuzumab prevents acute graft-vs-host disease (aGVHD) in non-myeloablative stem cell transplants (NST) from unrelated donors. Proc Am Soc Clin Oncol 2003.

 Buckanovich R, Porter DL.: Polycythemia Vera. Conn’s Current Therapy 55th edition. Rakel RE and Bope ET (eds.). Page: 503-506, 2003.

 Loren AW, Tsai DE, Porter DL, Stadtmauer EA.: Posttransplant lymphoproliferative disorder: A review. Bone Marrow Transplant 31: 145-155, 2003.

 Porter DL, Stadtmauer EA, Lazarus H. : "GVHD": Graft-vs-Host Disease or Graft-vs-Hodgkin's Disease? An Old Acronym with New Meaning. Bone Marrow Transplant 31: 739-746, 2003.

 Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R, Drobyski W, Barrett AJ, Porter DL Giralt S, Horowitz M, Leis J, Johnson MP, Collins RH.: Chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies following allogeneic stem cell transplantation. J Clin Oncol 20: 405-412, 2002.

 Cohen AD, Luger SM, Sickles C, Mangan PA, Porter DL, Schuster SJ, Tsai DE, Nasta S, Gewirtz AM, Stadtmauer EA.: Gemtuzumab Ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant 30: 23-28, 2002.

 French LE, Alcindor R, Shapiro M, Margolis DJ, Porter D, Leonard DGB, Rook AH, Foss F.: Identification of amplified clonal T cell populations in the blood of patients with chronic graft versus host disease: positive correlation with response to photopheresis. Bone Marrow Transplant 30: 509-515, 2002.

 Bilenker JH, Demers R, Porter DL, Wasserstein AG., MD, Maniker, S.: Recombinant Human Erythropoietin Usage in a Large Academic Medical Center. American Journal of Managed Care 8: 742-747, 2002.
back to top
Last updated: 11/24/2009
The Trustees of the University of Pennsylvania